MA-LINEDATA
19.10.2020 08:32:07 CEST | Business Wire | Press release
Linedata (Paris:LIN) (LIN:FP), a global provider of credit and asset management technology, data and services, unveiled its latest innovation, Asset Management Platform – Linedata AMP. The dynamic suite of tools provides asset managers with an always-on approach to software, data and services by leveraging cloud technology to offer continuous integration and drive adaptability.
The rapidly changing nature of the asset management industry has increased the pressures to adapt to digital transformation, overcome regulatory hurdles, streamline business costs and meet the needs of a globalized customer base. Linedata created AMP with a modular design to help the industry solve these challenges and ensure asset managers can constantly and quickly serve their customers.
“Linedata AMP was developed with more than 20 years of business intelligence expertise in mind. The platform enables clients to embrace market volatility and remote work demands with a trusted partner, who can simultaneously help them reimagine their operations and drive new business growth,” said Gary Brackenridge, Linedata’s Global Head of Asset Management. “By adopting AMP into business models, clients can utilize quick-to-market features, greater scalability, and cloud-enabled technology, while continuing to benefit from Linedata’s robust, interoperable technology and expert teams.”
Core features within Linedata AMP to improve the client experience include:
- Continuous Integration / Continuous Delivery (CI/CD) Platform – CI/CD makes Linedata AMP an ideal solution to boost innovation and expand into new markets. The seamless migration and simplified approach to upgrades makes incorporating new features possible at any time, with limited effort.
- Cloud-Based System – With AMP, Linedata is able to deploy a nimble, forward-compatible offering delivering a hassle-free user experience (UX) and user interface (UI), enhancing efficiency while increasing scalability – all in the public cloud, in addition to existing hybrid and private cloud options as well. Essential for an industry with work-from-home mandates and the need for enhanced security during remote working.
- Linedata Analytics Service (AI/ML) – Another key AMP offering is Linedata Analytics Service, which incorporates Artificial Intelligence (AI) and Machine Learning (ML) to deliver actionable insights from client and third-party data that asset managers can leverage to improve day-to-day processes, competitiveness in the marketplace and fundamentally lower cost curves.
- Linedata Data Management Service – Additionally, AMP includes Linedata Data Management Service, which lowers total cost of ownership for this critical function with comprehensive pricing and reference data sets directly integrated into Linedata software.
To learn more about Linedata’s Asset Management Platform – Linedata AMP, visit www.linedata.com/amp .
ABOUT LINEDATA
With 20 years’ experience and 700+ clients in 50 countries, Linedata’s 1300 employees in 20 offices provide global humanized technology solutions and services for the asset management and credit industries that help its clients to evolve and to operate at the highest levels.
Headquartered in France, Linedata achieved revenues of EUR 169.7 million in 2019 and is listed on Euronext Paris compartment B FR0004156297-LIN – Reuters LDSV.PA – Bloomberg LIN:FP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201018005023/en/
Social Media:
https://www.facebook.com/pages/category/Information-Technology-Company/Linedata-322170334263/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom